Kian Karimi
Facial Plastic Surgery · Los Angeles, CANPI 1073603262
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $755,623 of the $1,207,032 with a category attached, or 62.6%. 16 manufacturers reported payments, led by Galderma Laboratories, L.p. at 51.0% of the total. Among facial plastic surgery clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 885 payments — averaging $1363.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Galderma Laboratories, L.p.$615K
- AbbVie$547K
- Revance Therapeutics, Inc.$30K
- Merz North America, Inc.$14K
- Stryker$384
- Acclarent, Inc$233
- plus $486 from 10 others
Across 8 payments — averaging $2454.59 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$20K
What the payments were for
- Consulting fees$192,22616%
- Speaking & faculty fees$755,62363%
- Grants$138,15311%
- Travel & lodging$79,1007%
- Food & beverage$34,4303%
- Education$7,5001%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Galderma Laboratories, L.p. | 485 | $615,231 |
| AbbVie(2 entities) | 310 | $546,650 |
| Revance Therapeutics, Inc. | 33 | $29,573 |
| Merz North America, Inc. | 23 | $14,476 |
| Stryker | 5 | $384 |
| Acclarent, Inc | 5 | $233 |
| Optinose US, Inc. | 9 | $160 |
| Musculoskeletal Transplant Foundation Inc. | 3 | $92 |
| Smith+Nephew | 5 | $88 |
| Implant Direct Sybron International LLC | 1 | $42 |
| Sanofi | 1 | $23 |
| Regeneron Healthcare Solutions, Inc. | 1 | $22 |
| Novartis | 1 | $18 |
| Acelrx Pharmaceuticals, Inc. | 1 | $16 |
| Intersect ENT, Inc. | 1 | $14 |
| Amgen | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- BOTOX$302,351
- BOTOX COSMETIC$32,674
- DAXXIFY$28,504
- XEOMIN$2,033
- KYBELLA$1,950
- DYSPORT$729
- ASCLERA$200
- ENTELLUS - XPRESS ENT DILATION SYSTEM$133
- ENTELLUS - FIAGON SINUS NAVIGATION SYSTEM$130
How this compares
$1,207,032 in reported general payments places this provider in the 95th percentile of 120 facial plastic surgery providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Doxycycline Hyclate | 11 | $59 |
Paid to pharmacies, not to this prescriber.
Other facial plastic surgery in Los Angeles
- Geoffrey TrenkleLos Angeles$44K
- Behrooz TorkianLos Angeles$15K
- Amit KochharLos Angeles$4K
- Daniel SukatoLos Angeles$2K
- Carlo HonradoLos Angeles$2K
- Anna HsuLos Angeles$2K
- Henry ChenLos Angeles$1K
- Steven LeeLos Angeles$1K
- Nicholas SchenckLos Angeles$1K
- Andrew ChoiLos Angeles$1K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.